RBC Capital Maintains Outperform on Teladoc Health, Lowers Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Sean Dodge maintains an Outperform rating on Teladoc Health (NYSE:TDOC) but lowers the price target from $18 to $9.
August 01, 2024 | 5:28 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
RBC Capital analyst Sean Dodge maintains an Outperform rating on Teladoc Health but significantly lowers the price target from $18 to $9.
The significant reduction in the price target from $18 to $9 suggests a more cautious outlook on Teladoc Health's future performance, which could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100